Cidara Therapeutics (NASDAQ:CDTX – Get Free Report)‘s stock had its “strong-buy” rating reiterated by stock analysts at WBB Securities in a note issued to investors on Thursday, Benzinga reports. They currently have a $40.00 price target on the biotechnology company’s stock. WBB Securities’ price target would indicate a potential upside of 207.69% from the stock’s […]